Plural

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Plural, Cell, Science, Coffee, Research, Elective surgery, 3D, OA, Carbon, MIW, Osteoarthritis, Education minister, Facial muscles, PLUR

Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation.

Key Points: 
  • Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation.
  • The Company is leveraging two decades of experience and know-how in cell manufacturing to drive the future of coffee science.
  • Pluri’s Chief Executive Officer & President Yaky Yanay will participate in a panel of discussions and Chief Business Development Officer of Pharma Efrat Kaduri will attend the event.
  • It demonstrated increased muscle strength in two clinical studies and is believed to induce systemic anti-inflammatory effect and to reduce post-operative oxidative stress.

Pluri Inc. Announces 1-for-8 Reverse Share Split

Retrieved on: 
Wednesday, March 27, 2024
Indian stock exchange, Biotechnology, Plural, Cell, CUSIP, NRS, PLUR, Nevada Revised Statutes, Security (finance)

After giving effect to the reverse share split of the Company’s Common Shares, each eight (8) Common Shares will be combined into one Common Share, such that the Company’s 41,816,959 Common Shares outstanding will be reduced to approximately 5,227,120 Common Shares outstanding (the “Reverse Share Split”).

Key Points: 
  • After giving effect to the reverse share split of the Company’s Common Shares, each eight (8) Common Shares will be combined into one Common Share, such that the Company’s 41,816,959 Common Shares outstanding will be reduced to approximately 5,227,120 Common Shares outstanding (the “Reverse Share Split”).
  • No fractional shares will be issued as a result of the reverse split as any fractional shares resulting from the reverse split will be rounded up to the nearest whole share on a per shareholder basis.
  • No additional Company or shareholder approval is required because both the number of authorized Common Shares and the number of outstanding Common Shares will be proportionally reduced as a result of the Reverse Share Split, the Reverse Share Split will not adversely affect any other class of shares of the Company and the Company will not pay money or issue scrip to shareholders who would otherwise be entitled to receive a fractional share as a result of the reverse split.
  • The reverse split will not impact any shareholder's percentage ownership of Pluri or voting power, except for minimal effects resulting from the treatment of fractional shares.

Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Retrieved on: 
Thursday, March 21, 2024
Deflation, Climate change, Taste, Biotechnology, Plural, Cell, International, Coffee, Nature Biotechnology, ICO, Water, Heat, Frost, PLUR, Maxwell House International, Report, Weather

Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.

Key Points: 
  • Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.
  • Pluri’s cell-based coffee aims to reduce price instability by moving coffee production into the lab, eliminating the effect of climate change and adverse weather conditions.
  • Pluri recently announced the launch of its cell-based coffee , its proprietary cultured coffee product business, part of its PluriAgtech vertical, addressing the $130 billion coffee industry.
  • To learn more about Pluri’s coffee see the recent article titled “Cell-Based Coffee Future-Proofs World’s Favorite Brew” in the leading peer-reviewed journal Nature Biotechnology.

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Retrieved on: 
Tuesday, March 19, 2024
Conference, Biotechnology, Plural, Cell, Environment, Allotransplantation, Education minister, Investment, Exhibition, PLUR, Pharmaceutical industry

BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings.

Key Points: 
  • BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings.
  • The Advanced Therapies congress is Europe’s largest cell and gene therapy conference and exhibition.
  • Pluri’s Chief Executive Officer & President Yaky Yanay will be presenting at the conference on Thursday, March 28, 2024 at 2:20 PM.
  • CISH Impact Investments Holdings Conference is a global event on impact opportunities and investments in promising technology companies that have a positive impact on the community and the environment.

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Retrieved on: 
Thursday, March 14, 2024
CDMO, Biotechnology, Plural, Cell, Survival, WCB, Partnership, Stem cell, Idiopathic pulmonary fibrosis, GMP, IPF, PLUR, Idiopathic disease, Cell bank, Pharmaceutical industry

HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.

Key Points: 
  • HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
  • PluriCDMO™ will support Remedy Cell’s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell’s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
  • Remedy Cell CEO, Ayelet Dilion-Mashiah, said, “This is an exciting time at Remedy Cell as we initiate the early stages of clinical development of our novel drug candidate, RC-0315, for IPF, a condition with significant unmet treatment needs.
  • We are delighted that Remedy Cell has chosen PluriCDMO™ to assist with their clinical manufacturing, and we eagerly anticipate the establishment of a robust, long-term partnership grounded in excellence and collaboration."

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Politics, Public policy, Regenerative medicine, Massachusetts Democratic Party, PLUR, Social, Public health, Government, Affordable Care Act, Plural, Cell, Rule, Health, Social Security, Private sector, Medicare, Harvard Kennedy School, Cambridge Public Library, Patient, Knowledge, Democratic National Committee, Medicaid, National Committee, Quality assurance, Tufts Health Plan

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.

Key Points: 
  • HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.
  • The intersection of public policy and health is a passion for him.
  • As CEO of Tufts Health Plan, his leadership achieved consistent profitability while attaining the #1 ranking from the National Committee for Quality Assurance.
  • Mr. Roosevelt is also a trustee of the Cambridge Public Library, the Cambridge Community Foundation, and the Atrius Health Equity Foundation.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024
Infection, Therapy, Bangladesh Technical Education Board, Parity, AFRRI, USUHS, Cocaine, Medicine, NIAID, NIH, Bar-Ilan University, PLUR, World War II, FDA, PLX, Partnership, 3D, Food, Ageing, GMP, Hope, BIRAD, Plural, Meat, Risk, Outline of health sciences, CDMO, Climate, Climate change, Health, Water, Food and Drug Administration, Coffee, Knowledge, Agriculture, Food security, Negotiation, Good manufacturing practice, Pharmaceutical industry

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

Meatable Strengthens Board of Directors to Accelerate Growth of Breakthrough Food Technology

Retrieved on: 
Thursday, February 15, 2024
Technology, Retail, Food Tech, Food, Beverage, DSM, Research, Master of Science, Biotechnology, Multimedia, Chemistry, Food technology, University, Liberty Media, General partnership, TSX, McGill University, Marketing, Columbia Business School, Syngenta, MBA, Plural, Meat, Health, CAD, Mood Media, FUN Technologies, Toxicology, Science, Food security, Biology, Novozymes, Development, Head, Management

“Meatable is at an exciting juncture in our growth trajectory as we prepare to launch our consumer products in Singapore and host our first tasting in the EU.

Key Points: 
  • “Meatable is at an exciting juncture in our growth trajectory as we prepare to launch our consumer products in Singapore and host our first tasting in the EU.
  • On the Meatable Board, Mr. Abony will support the company’s management team by advising on commercial development initiatives in the U.S. as well as future transactions.
  • “Compared to others in its category, Meatable is highly differentiated through its industry-first technology and phased approach.
  • “Meatable is working at the forefront of food technology and is a clear-cut leader in the cultivated meat space,” said Ms. Malarkey.

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Retrieved on: 
Tuesday, January 23, 2024
Plural, Agriculture, Carbon, Water, Coffee, Intellectual property, PLUR, Cell

Pluri’s cell-based coffee product is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production.

Key Points: 
  • Pluri’s cell-based coffee product is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production.
  • PluriAgtech’s cell-based coffee has been developed to deliver authentic coffee while solving key challenges faced by the industry.
  • Compared to traditional methods of coffee production, Pluri’s cell-based coffee is estimated to slash water usage by 98%.
  • “We are uniquely positioned to transform the coffee industry with our sustainable cell-based coffee,” said Michal Ogolnik.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023
Bar-Ilan University, Cocaine, Depression, FDA, Crime, PLUR, Pharmaceutics, Plural, PLX, Brain, Drug, Research, Rat, BIRAD, PTSD, Anxiety, U.N, Neurogenesis, Cell, Neuron, PAD, Pharmaceutical industry

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.